专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US09121846B2 Daikenchuto bioassay method and quality management method using same 有权
标题翻译： Daikenchuto生物测定方法和质量管理方法使用相同
公开(公告)号：US09121846B2
公开(公告)日：2015-09-01
申请号：US13991174
申请日：2011-11-28
申请人： Atsushi Kaneko , Nagisa Ohno
发明人： Atsushi Kaneko , Nagisa Ohno
IPC分类号： G01N33/50 , G01N33/94
CPC分类号： G01N33/5008 , G01N33/5064 , G01N33/507 , G01N33/94 , G01N33/942 , G01N2333/415 , G01N2333/70571
摘要： The invention intends to provide a bioassay method using a simple in-vitro test for Daikinchuto, and further to provide a more highly accurate method for quality control of Daikenchuto using the same. These methods are a bioassay method for the pharmacological activity of Daikenchuto, characterized in that a test sample containing Daikenchuto is added to cultured serotonin-producing cells, and the serotonin content in the culture supernatant is subsequently measured; and a quality control method for Daikenchuto preparations in which the pharmacological activity of a test preparation and a reference preparation for which the pharmacological effect as Daikenchuto has been clinically confirmed are evaluated under the same conditions, and the equivalence of the reference preparation and testing preparation is evaluated.
摘要翻译：本发明旨在提供一种使用大金刚藤的简单体外试验的生物测定方法，并且进一步提供使用该方法的更高精度的用于质量控制的Daikenchuto方法。这些方法是Daikenchuto的药理活性的生物测定方法，其特征在于，将含有Daikenchuto的试验样品加入培养的产生血清素的细胞中，随后测量培养上清液中的5-羟色胺含量; 以及在相同条件下对具有Daikenchuto的药理作用临床确认的试验制剂和对照制剂的药理活性进行评价的大连烧制剂的质量控制方法，参考制剂和试验制剂的等效性为评估。

2. 发明授权

US08871962B2 Method for producing sanshool 有权
标题翻译：生产学校的方法
公开(公告)号：US08871962B2
公开(公告)日：2014-10-28
申请号：US13988401
申请日：2011-11-28
申请人： Katsuyuki Aoki
发明人： Katsuyuki Aoki
IPC分类号： C07F15/02 , C07C231/12 , C07C233/12
CPC分类号： C07C231/12 , C07F15/02 , C07C233/09 , C07C233/20
摘要： Provided are a method for producing a sanshool, which method has a short process and exhibits high stereoselectivity, as well as an iron carbonyl complex compound that is an intermediate useful for the production method.A diene iron complex compound characterized by being represented by the following general formula (I): (in which A represents CO, P(RA)3, CN, NO, SO(RA)3, or N(RA)2; RA represents a straight chain or branched chain alkyl group having 1 to 4 carbon atoms or an aryl group having 6 to 12 carbon atoms; and one of R1 and R2 represents a hydrogen atom and the other one thereof represents a structure represented by the following formula (II)): (in which R represents a hydrogen atom, a hydroxyl group, or a methyl group).
摘要翻译：本发明提供了一种生产方法，该方法具有短的工艺并具有高立体选择性，以及作为制备方法有用的中间体的羰基铁配合物。一种二烯铁络合物，其特征在于由以下通式（I）表示：（其中A表示CO，P（RA）3，CN，NO，SO（RA）3或N（RA）2）具有1至4个碳原子的直链或支链烷基或具有6至12个碳原子的芳基; R 1和R 2之一表示氢原子，并且其中之一表示由下式（II ））:(其中R表示氢原子，羟基或甲基）。

3. 发明授权

US08428883B2 Multi-component medicine evaluation method 有权
标题翻译：多组分药物评价方法
公开(公告)号：US08428883B2
公开(公告)日：2013-04-23
申请号：US11628764
申请日：2005-06-06
申请人： Kouya Yano , Naoko Hattori
发明人： Kouya Yano , Naoko Hattori
IPC分类号： G01N33/48 , G01N31/00 , G06G7/48
CPC分类号： G01N30/8675 , G01N30/8686 , G01N2030/8809 , G01N2030/8813
摘要： A method for evaluation of a multi-component medicine by judging the degree of difference of the multi-component medicine to be evaluated from a group of multi-component medicines selected as a reference group by using a Mahalanobis distance obtained by combining the 3D-HPLC fingerprint data of a multi-component medicine with fingerprint data of 3D-HPLC of other multi-component medicines of the same kind forming a reference group, allocating variable axes in the MT method to the number of multi-component medicine and the elution time or detection wavelength of the fingerprint data, obtaining a unit space from the signal strength, and obtaining the Mahalanobis distance of the multi-component medicine from the unit space.
摘要翻译：通过使用通过组合3D-HPLC获得的马哈拉诺比斯距离来判断从被选择为参考组的一组多组分药物中评估的多组分药物的差异程度来评估多组分药物的方法多组分药物的指纹数据与其他相同类型多组分药物的3D-HPLC指纹数据形成参考组，MT方法中的可变轴分配到多组分药物的数量和洗脱时间，或指纹数据的检测波长，从信号强度获得单位空间，以及从单位空间获得多组分药物的马氏距离。

4. 发明申请

US20110111426A1 METHOD OF BIOASSAYING YOKUKANSAN 有权
标题翻译：生活方式YOKUKANSAN
公开(公告)号：US20110111426A1
公开(公告)日：2011-05-12
申请号：US13000029
申请日：2008-06-27
申请人： Yasushi Ikarashi , Zenji Kawakami , Kiyoshi Terawaki
发明人： Yasushi Ikarashi , Zenji Kawakami , Kiyoshi Terawaki
IPC分类号： G01N33/53
CPC分类号： A61K36/48 , G01N33/566 , G01N2333/70571 , G01N2500/02
摘要： The invention intends to find out a bioassay system with an in-vitro test capable of ensuring the higher quality of yokukansan, and provides a bioassay method for yokukansan, comprising competitively reacting a labeled ligand and yokukansan with cells or cell membranes expressing glutamate receptors, measuring the binding activity of yokukansan, and evaluating the pharmacological activity value of yokukansan from the measurement value.
摘要翻译：本发明旨在找出具有能够确保更高质量的洋甘康素的体外试验的生物测定系统，并且提供了一种用于洋葱素的生物测定方法，其包括使标记的配体和Yokukansan与表达谷氨酸受体的细胞或细胞膜竞争性地反应，测量 yokukansan的结合活性，并从测定值评价yokukansan的药理活性值。

5. 发明授权

US6127519A Calcitonin derivatives 失效
标题翻译：降钙素衍生物
公开(公告)号：US6127519A
公开(公告)日：2000-10-03
申请号：US401432
申请日：1990-12-21
申请人： Ronald C. Orlowski , Satoshi Hanamura , Masahiko Marumoto , Kenji Sakamoto , Yoshihiro Waki
发明人： Ronald C. Orlowski , Satoshi Hanamura , Masahiko Marumoto , Kenji Sakamoto , Yoshihiro Waki
IPC分类号： A61K38/00 , A61K38/23 , A61P3/00 , A61P3/14 , A61P5/00 , A61P29/00 , A61P43/00 , C07K7/54 , C07K14/585 , C07K17/00
CPC分类号： C07K14/585 , A61K38/00
摘要： Peptides useful in the regulation of calcium metabolism are disclosed. Also disclosed are pharmaceutical compositions of matter containing such peptides as well as a method for the regulation of calcium metabolism in a patient in need of such treatment. The peptides contain modified or unmodified portions of an amino acid sequence at the 8- to 32-positions of native calcination.
摘要翻译： PCT No.PCT / US90 / 02143 Sec。 371 1990年12月21日第 102（e）1990年12月21日日期PCT提交1990年4月19日PCT公布。公开号WO90 / 12809 日期1990年11月1日公开了可用于调节钙代谢的肽。还公开了含有这些肽的物质的药物组合物以及在需要这种治疗的患者中调节钙代谢的方法。肽在天然煅烧的8至32位含有氨基酸序列的修饰或未修饰部分。

6. 发明授权

US5968899A Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption 失效
标题翻译：具有EACA或氨甲环酸的肽的药物组合物用于增强粘膜吸收
公开(公告)号：US5968899A
公开(公告)日：1999-10-19
申请号：US737930
申请日：1996-12-02
申请人： Takashi Sekine , Kazuyuki Ishikawa , Takayoshi Kimura , Yoshinobu Nakai
发明人： Takashi Sekine , Kazuyuki Ishikawa , Takayoshi Kimura , Yoshinobu Nakai
IPC分类号： A61K38/23 , A61K47/10 , A61K47/18 , A61K38/17 , A61K38/09 , A61K38/10 , A61K38/16
CPC分类号： A61K47/183 , A61K38/23 , A61K47/10 , A61K9/0019 , Y10S514/802
摘要： Disclosed is a medicinal composition, which comprises a peptide as an effective ingredient and as bases, epsilon aminocaproic acid or tranexamic acid and an ethylene oxide-propylene oxide block copolymer represented by the following formula (I):HO(C.sub.2 H.sub.4 O).sub.a --(C.sub.3 H.sub.6 O).sub.b --(C.sub.2 H.sub.4 O).sub.c H (I)wherein a, b and c stand for integers of 1 or greater, respectively. According to this medicinal composition, the peptide can be absorbed at a high rate through the mucosa and further, its pharmacological effects are prolonged over for a long time.
摘要翻译： PCT No.PCT / JP95 / 01085 Sec。 371日期1996年12月2日第 102（e）日期1996年12月2日PCT归档1995年6月2日PCT公布。 WO95 / 33474 PCT公开号日期：1995年12月14日公开是药物组合物，其包含作为有效成分的肽和作为碱的ε氨基己酸或氨甲环酸和由下式（I）表示的环氧乙烷 - 环氧丙烷嵌段共聚物：HO（C 2 H 4 O ）a-（C 3 H 6 O）b - （C 2 H 4 O）c H（I）其中a，b和c分别表示1或更大的整数。根据该药物组合物，可以通过粘膜以高速率吸收肽，并且其药理作用长时间延长。

7. 发明授权

US5318798A Process for producing kampo medicine hard capsules 失效
标题翻译：制作k o药硬胶囊的方法
公开(公告)号：US5318798A
公开(公告)日：1994-06-07
申请号：US941800
申请日：1992-09-08
申请人： Toshihiro Uchida , Shin'ichiro Konishi , Takayoshi Kimura
发明人： Toshihiro Uchida , Shin'ichiro Konishi , Takayoshi Kimura
IPC分类号： A61K9/16 , A61K9/48 , A61K36/00 , A61K36/23 , A61K36/258 , A61K36/28 , A61K36/539 , A61K36/718 , A61K36/725 , A61K36/744 , A61K36/756 , A61K36/9066 , B01J13/02
CPC分类号： A61K9/4858 , A61K36/00 , A61K36/23 , A61K36/258 , A61K36/28 , A61K36/539 , A61K36/718 , A61K36/725 , A61K36/744 , A61K36/756 , A61K36/9066 , A61K9/1611 , A61K9/1652 , Y10S514/962 , Y10S514/974
摘要： When a powdered extract of Kampo medicine is encapsulated as such in hard capsules, the pharmaceutical effects of the Kampo medicine cannot be fully achieved, since the dissolution of the content of the hard capsules requires a long period of time. Therefore, the present invention aims at providing Kampo medicine hard capsules having good dissolution properties.The present invention provides a process for producing Kampo medicine hard capsules which comprises compacting Kampo medicine extract powder, mixing magnesium stearate with the compacted Kampo medicine extract powder and filing the mixture into gelatin hard capsules.It is preferable that the weight ratio of the magnesium stearate to the Kampo medicine powdered extract ranges from 0.5/100 to 3/100. Furthermore, it is preferable that said Kampo medicine is selected from Oren-gedoku-to, Sho-saiko-to, Ninjin-to, San'o-shashin-to, Mao-bushi-saishin-to, Anchu-san, Keishi-bukuryo-gan, Byakko-ka-ninjin-to, Shakuyaku-kanzo-to and Sairei-to.
摘要翻译：当汉方医药的粉末提取物如此包装在硬胶囊中时，由于硬胶囊的内容物的溶解需要较长的时间，所以不能完全达到汉方药物的药效。因此，本发明的目的在于提供具有良好溶解性能的汉方药用硬胶囊。本发明提供了一种生产汉方药物硬胶囊的方法，其包括压制汉方药物提取物粉末，将硬脂酸镁与压实的汉方药物提取物粉末混合并将混合物倒入明胶硬胶囊中。优选硬脂酸镁与汉方药粉末提取物的重量比为0.5 / 100〜3/100。此外，优选的是，所述汉方药物选自Oen-gedoku-to，Sho-saiko-to，Ninjin-to，Sano-shashin-to，Mao-bushi-saishin-to，Anchu-san，Keishi- buakuryo-gan，Byakko-ka-ninjin-to，Shakuyaku-kanzo-to和Sairei-to。

8. 发明授权

US5214174A Platinum complex and anti-tumor agent comprising said complex as active ingredient 失效
标题翻译：白蛋白复合物和包含作为活性成分的复合物的抗肿瘤剂
公开(公告)号：US5214174A
公开(公告)日：1993-05-25
申请号：US752462
申请日：1991-10-15
申请人： Ken Miyamoto , Yuichi Fujii , Toshiaki Fujihashi
发明人： Ken Miyamoto , Yuichi Fujii , Toshiaki Fujihashi
IPC分类号： C07F15/00
CPC分类号： C07F15/0093
摘要： Disclosed are a novel platinum complex represented by the following formula I or a steric isomer thereof, an anti-tumor agent comprising this complex as the effective ingredient, and a method of curing a tumor by using this complex: ##STR1## This complex is advantageous in that the toxicity is low and the anti-tumor activity is high.

9. 发明授权

US4987240A Novel biphenyl derivative and production and use thereof 失效
标题翻译：新型联苯衍生物及其制备及应用
公开(公告)号：US4987240A
公开(公告)日：1991-01-22
申请号：US450211
申请日：1989-11-21
申请人： Yoshiyuki Matsuoko , Kunio Hosaka , Shigefumi Takeda , Hiroshi Mitsuhashi
发明人： Yoshiyuki Matsuoko , Kunio Hosaka , Shigefumi Takeda , Hiroshi Mitsuhashi
IPC分类号： C07D317/68 , A61K31/357 , A61K31/36 , A61P1/16
CPC分类号： C07D317/68
摘要： The present invention relates to a novel biphenyl derivative having a liver ailment-moderating action, which is effective for the remedy of liver diseases such as acute hepatitis and chronic hepatitis, a process for the preparation of this derivative and a liver ailment-moderating agent comprising this derivative as an active ingredient. Moreover, the present invention relates to a compound valuable as the intermediate compound for the synthesis of this derivative and a process for efficiently preparing this intermediate compound.

10. 发明授权

US4904694A Biphenyl derivative useful in the treatment of liver diseases 失效
标题翻译：联苯衍生物可用于治疗肝脏疾病
公开(公告)号：US4904694A
公开(公告)日：1990-02-27
申请号：US180107
申请日：1988-02-10
申请人： Yoshiyuki Matsuoka , Kunio Hosaka , Shigefumi Takeda , Hiroshi Mitsuhashi
发明人： Yoshiyuki Matsuoka , Kunio Hosaka , Shigefumi Takeda , Hiroshi Mitsuhashi
IPC分类号： C07D317/68 , A61K31/357 , A61K31/36 , A61P1/16
CPC分类号： C07D317/68
摘要： The present invention relates to a novel biphenyl derivative having a liver ailment-moderating action, which is effective for the remedy of liver diseases such as acute hepatitis and chronic hepatitis, a process for the preparation of this derivative and a liver ailment-moderating agent comprising this derivative as an active ingredient. Moreover, the present invention relates to a compound valuable as the intermediate compound for the synthesis of this derivative and a process for efficiently preparing this intermediate compound.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式